Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
MTHFRA1298C and PAI-1 deletions were most frequent genetic variants in risk groups for MI in patients with diabetes mellitus (value of odds ratio sequentially [OR] = 3.79, p = 0.06 and [OR] = 5 × 10(8), p = 0.000).
|
22752805 |
2012 |
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Our meta-analyses suggest that the PAI-1 -675 4G/5G polymorphism might not be a risk factor for DM, DN, DR or diabetic CAD risk in the populations investigated.
|
24223897 |
2013 |
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Interaction between genotype and diabetes status was estimated for nine CVD risk factors [body fat mass (FAT), body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), log-transformed fibrinogen, log-transformed triglycerides, log-transformed urinary albumin : creatinine ratio (LACR), plasminogen activator inhibitor 1 (PAI-1), systolic blood pressure (SBP), and waist-to-hip ratio (WHR)], using a maximum likelihood variance decomposition technique.
|
12673782 |
2003 |
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Low-moderate arsenic exposure was positively associated with baseline fibrinogen in participants with diabetes and unexpectedly inversely associated with PAI-1.
|
28771557 |
2017 |
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The PAI-1 and ACE (D/I) gene polymorphisms were examined in a cohort of Chinese type 2 diabetic patients who had diabetes for an average of 14 years.
|
10652041 |
2000 |
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
|
21070757 |
2011 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Four proteins (Scavenger receptor cysteine rich type 1 protein M130, Fatty acid binding protein 4, Plasminogen activator inhibitor 1 and Insulin-like growth factor-binding protein 2) with a previously established association with incident diabetes and 3 proteins (Cathepsin D, Galectin-4, Paraoxonase type 3) with a novel association with incident diabetes.
|
30670722 |
2019 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
However, inflammatory biomarkers hs-CRP [hazard ratio (HR) 1.16, (95% CI 1.05 to 1.29), p=0.005], procalcitonin [HR 1.34, (95% CI 1.07 to 1.69), p=0.012] and PAI-1 [HR 1.55, (95% CI 1.37 to 1.75), p<0.001] remained significantly associated with new-onset DM, even after multivariable adjustment for established predictors of DM.
|
29074040 |
2018 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
We recently revealed that plasminogen activator inhibitor-1 (PAI-1), a serine protease inhibitor, is involved in diabetes, osteoporosis and muscle wasting induced by glucocorticoid (GC) treatment in mice.
|
28321652 |
2018 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.
|
9844142 |
1998 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
The aim was to evaluate tissue plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) concentration using enzyme linked immunosorbent assay method (ELISA) in diabetic foot syndrome (DFS) as compared to a group of healthy people and patients with diabetes mellitus without symptomatic vascular complications (DM2T).
|
28193577 |
2017 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Since TGF-beta1 is well known to stimulate the PAI-1 promoter, we suggest that TGF-beta1 and PAI-1 together constitute a positive feedback loop in the development of renal fibrosis in diabetes.
|
19786738 |
2009 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Concentrations in blood of plasminogen activator inhibitor type 1 (PAI-1) and circulating free (non-esterified) fatty acids (FFA) are increased in diabetes and may accelerate atherosclerosis.
|
12669679 |
2002 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Compared with 55 (33.3%) individuals in whom OSAS was not confirmed, OSAS patients had prolonged CLT (+12.8%), associated with higher PAI-1 antigen (+18.1%) (after adjustment for age, diabetes, and body mass index; both P < 0.01) and similar levels of TAFIa, plasmin, or antiplasmin.
|
27167858 |
2016 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Myocardial mRNA levels of interleukin-6, tumor necrosis factor-α, plasminogen activator inhibitor-1, angiotensin type 1 receptor, angiotensinogen, NADPH oxidase subunits (p47(phox), gp91(phox)), glutathione peroxidase-3. and connective tissue growth factor were increased in CRP/DM compared with Wt/DM.
|
21519150 |
2011 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that a PAI-1 specific inhibitor alleviated diabetes-induced delays in skin and muscle repair.
|
29311999 |
2017 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Increased flux through HBP is required and sufficient for some of the metabolic effects of sustained, increased glucose flux, which promotes the complications of diabetes, e.g., diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase in cardiomyocytes and induction of TGF-beta and plasminogen activator inhibitor-1 in vascular smooth muscle cells, mesangial cells, and aortic endothelial cells.
|
16339923 |
2006 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin.
|
11887975 |
2001 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1), produced partly from liver is a risk factor for macrovascular and microvascular complications of diabetes.
|
18700166 |
2008 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Patients most likely to benefit from PAI-1 inhibition would be those at high risk for vascular events where PAI-1 is elevated, such as is observed in obesity, diabetes and the metabolic syndrome.
|
17896948 |
2007 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Elevated plasminogen activator inhibitor-1 may contribute to vascular disease in diabetes mellitus.
|
8960834 |
1996 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
From our longitudinal cohort study, we selectively recruited chronically stable HIV-infected individuals without diagnosis of diabetes mellitus at baseline (N = 62) to analyze the correlation of baseline inflammatory cytokines, including PAI-1 and whole-body insulin sensitivity, with 2-year follow-up, as measured by Matsuda Index.
|
28322572 |
2017 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice.
|
25552599 |
2015 |
Diabetes Mellitus
|
0.300 |
Therapeutic
|
group |
RGD |
Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats.
|
10910004 |
2000 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
PAI-1 deficiency did not affect the mRNA levels of iNOS and IL-6 in F4/80- and CD11b-double-positive cells from the bone marrow of the damaged femurs decreased by diabetes in mice.
|
29534207 |
2018 |